It's a wrap! MDF held its fifth annual conference on November 8-10 in Houston, Texas to a sold-out crowd of 300 community members, caregivers, academic researchers and their program and lab partners, and pharmaceutical company representatives.
Disclosing and Talking About Your Disorder
In late September, Barry Cohen–-a licensed consulting psychologist and experienced caregiver for his now deceased wife and adult son with DM1–-facilitated our webinar title “Disclosing and Talking about Your Disorder.”
Dr. Peter Harper wrote what many people living with DM believe is the best lay overview of myotonic dystrophy in existence in a book entitled "The Facts: Myotonic Dystrophy."
Researchers have published several recent studies on advances in DM research.
Ionis Pharmaceuticals (formerly Isis Pharmaceuticals, Inc.) announced the identification of a drug development candidate, IONIS-DMPKRx, designed to treat Myotonic Dystrophy Type 1 (DM1), which they plan to advance into human clinical trials next year.